BioMarin Maintained as 'Strong Buy' Following Amicus Acquisition and VOXZOGO Expansion

Key Facts

1BioMarin's acquisition of Amicus Therapeutics boosted 2026 revenue guidance to $3.825–$3.925 billion.

2The company targets 20% YoY growth with topline Phase 3 data for VOXZOGO expected in Q2 2026.

BioMarin Pharmaceutical has maintained its 'Strong Buy' rating following the strategic acquisition of Amicus Therapeutics and the expansion of its VOXZOGO pipeline. The acquisition has significantly boosted the company's 2026 revenue guidance to a range of $3.825–$3.925 billion, integrating key treatments like GALAFOLD into its portfolio. BioMarin is now targeting a 20% year-over-year growth rate, driven by clinical progress and market expansion. Investors are closely watching for topline Phase 3 data for VOXZOGO, which is expected to be released in Q2 2026. This clinical milestone, combined with M&A synergies, provides a robust long-term catalyst for the stock. The analyst reiteration reflects confidence in the company's ability to scale its operations and deliver consistent value in the biotech sector.